Last reviewed · How we verify

NCT04739124: APPRO-FSL

Appropriation of the Connected Solution Freestyle Libre® in Adult Patients With Diabetes in the Context of Therapeutic Education

Completed Last updated 21 September 2023
What this trial tests

trial testing Follow-up questionnaires in Diabetes in 86 participants. Completed in 6 September 2023.

Timeline
10 June 2021
Primary endpoint
6 September 2023
6 September 2023

Quick facts

Lead sponsorDirection Centrale du Service de Santé des Armées
StatusCompleted
Study typeOBSERVATIONAL
Enrollment86
Start date10 June 2021
Primary completion6 September 2023
Estimated completion6 September 2023
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Direction Centrale du Service de Santé des Armées — full company profile →

Who can join

18 and older, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Following the proposal to self-monitor by the Freestyle Libre® (FSL) connected object, in diabetic patients in the context of therapeutic education, regarding the appropriation of FSL, what works, for which patients , in what specific contexts and by what mechanisms does it govern? A multicentric observational research will be conducted with mixed method design (follow-up using patient questionnaires) and semi-structured interviews of patients and caregivers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

Other Direction Centrale du Service de Santé des Armées trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04739124.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing